Excellent results form this study!
What are shareholders thoughts on only a 3 year market exclusivity impacting the valuation ?
I do expect this business to be taken over slightly before final FDA approval by a big pharma, but have concerns that 3 years may not be long enough.
It is true that the first product to market will still maintain roughly 50% of its market share in the first year out of exclusivity, however I worry this limits the value of the company from an acquisition standpoint.
Ann: SPONTAN achieves positive clinical study results, page-70
-
- There are more pages in this discussion • 116 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add LTP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
73.0¢ |
Change
-0.065(8.18%) |
Mkt cap ! $61.89M | |||
| Open | High | Low | Value | Volume |
| 79.5¢ | 79.5¢ | 72.0¢ | $746.8K | 995.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9000 | 72.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 73.0¢ | 7651 | 1 |
View Market Depth
| Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
| LTP (ASX) Chart |